CAR-T Cell-Derived Exosomes and Cancer Immunotherapy: Advancing Production and Delivery Through Biofabrication

Area of Science:

• Immunology
• Bioengineering
• Translational Medicine

Background:

• CAR T-cell therapy shows promise for hematologic cancers but faces challenges in solid tumors, including poor infiltration and immunosuppressive microenvironments.
• CAR T-cell derived exosomes (CAR-T-EXOs) are emerging as acellular alternatives, offering tumor-specific recognition and cytotoxic functions while mitigating severe toxicities like cytokine release syndrome (CRS) and neurotoxicity.
• Nanosized CAR-T-EXOs can effectively penetrate dense tumor stroma and reprogram immunosuppressive niches, presenting a potential advantage over cellular therapies.

Purpose of the Study:

• To review the biological advantages of CAR-T-EXOs for solid tumor immunotherapy.
• To survey the latest biofabrication strategies for CAR-T-EXO production, validation, and delivery.
• To discuss the regulatory challenges and emerging paradigms for clinical translation of CAR-T-EXO-based therapies.

Main Methods:

• Review of current literature integrating immunology, bioengineering, and translational perspectives.
• Analysis of biofabrication techniques for high-yield CAR-T-EXO production and functional validation.
• Evaluation of smart delivery systems and biofabricated models (3D spheroids, organoids, tumor-on-chip) for exosome efficacy testing.

Main Results:

• CAR-T-EXOs demonstrate potential for improved tumor infiltration and reprogramming of the immunosuppressive tumor microenvironment.
• Advances in biofabrication enable scalable production and precise delivery of CAR-T-EXOs.
• Smart delivery systems and advanced models offer enhanced control and evaluation of exosome-based immunotherapies.

Conclusions:

• CAR-T-EXOs represent a promising next-generation immunotherapy for solid tumors, offering enhanced safety and efficacy.
• Overcoming challenges in isolation, characterization, and regulatory frameworks is crucial for clinical translation.
• Emerging paradigms like exosome mimetics and personalized tumor-on-chip testing are poised to accelerate the development of novel exosome-based immunotherapies.